Back to Archived Journals » International Journal of Interferon, Cytokine and Mediator Research » Volume 2

The role of constitutively activated STAT3 in B16 melanoma cells

Authors Yang CH, Meiyun Fan, Slominski A, Yue J, Pfeffer L

Published 7 January 2010 Volume 2010:2 Pages 1—7


Review by Single anonymous peer review

Peer reviewer comments 2

Chuan He Yang1, Meiyun Fan1, Andrzej T Slominski1, Junming Yue2, Lawrence M Pfeffer1

1Department of Pathology and Laboratory Medicine, 2Department of Physiology, University of Tennessee Health Science Center and the Center for Cancer Research, Memphis, TN, USA

Abstract: Constitutively activated STAT3 is found frequently in a wide variety of human tumors, including melanoma. Moreover, constitutive STAT3 activation actively participates in tumor formation and progression, making STAT3 an attractive target for cancer therapy. We report here that in murine B16 melanoma cells, which have been previously shown to express constitutively active STAT3, the expression of a mutant form of STAT3 with the canonical tyrosine phosphorylation site (residue 705) mutated to phenylanaine has dominant-negative properties (STAT3-DN). STAT3-DN inhibits STAT3 tyrosine phosphorylation and STAT3-dependent DNA binding activity. Most importantly, STAT3-DN expression in B16 cells inhibits their invasiveness, as well as their melanogenesis by down-regulation of tyrosinase mRNA and protein expression as well as tyrosinase activity. These results suggest that STAT3 signaling plays a critical role in regulating melanoma behavior, and may represent a druggable target for melanoma therapy.

Keywords: STAT3, melanoma, invasion, tyrosinase, melanogenesis

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.